title: Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
abstract: BACKGROUND
  Dyslipidemia management situation in Chinese patients with high risk and very high risk has been demonstrated very low, despite the wide use of statins. The effects and safety of the combined treatment of ezetimibe (EZ) and statins in Chinese patients with acute coronary syndrome (ACS) and type 2 diabetes mellitus (T2DM) remain unknown.
  
  
  METHODS
  Chinese Patients with ACS and T2DM were divided into the statins group (n=40) and the combination group of EZ and statins (n=44). In order to evaluate the clinical effects on lipids-lowering, systemic inflammation response and clinical safety, the follow-up of all patients was carried out at day 7th and 30th after treatment.
  
  
  RESULTS
  The level of low-density lipoprotein cholesterol (LDL-C) in combination group and statins group was 1.87±0.42 and 2.18±0.58 mmol/L at day 7th, 1.51±0.29 and 1.94±0.49 mmol/L at day 30th, respectively. The control rates of LDL-C level in the combination group and the statins group were 77% and 45% at day 30(th), respectively. There was no significant improvement on high-density lipoprotein cholesterol (HDL-C) level during follow-up. The triglyceride (TG) levels were significantly reduced in both groups, while no obvious difference was observed between two groups. No significant difference on serum high-sensitivity C-reactive protein (hs-CRP) level between two groups was observed. Moreover, we did not observe any significant correlation between serum lipids levels and serum hs-CRP level during follow-up. The liver dysfunction and muscle related side effects (MRSE), creatine kinase (CK) and myopathy were not observed in both groups.
  
  
  CONCLUSIONS
  Our study demonstrated that it is feasible to initiate combination therapy during acute phase for Chinese patients with ACS and T2DM, which can bring more significant effect on LDL-C-lowering and improve the control rate of LDL-C level with good safety.
authors: Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, China. charitelilulu@gmail.com.|Charite University of Berlin, Berlin, Germany. charitelilulu@gmail.com.
authors: Lulu
authors: L
authors: Li
authors: Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, China. zhangminli081208@163.com.
authors: Minli
authors: M
authors: Zhang
authors: Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, China. jacsue@163.com.
authors: Fuxiang
authors: F
authors: Su
authors: Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, China. liyang_mslm@163.com.
authors: Yang
authors: Y
authors: Li
authors: Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, China. shenyali_cmu@163.com.
authors: Yali
authors: Y
authors: Shen
authors: Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, China. shenjudith@163.com.
authors: Jie
authors: J
authors: Shen
authors: Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, China. zhangdaqing@vip.163.com.
authors: Daqing
authors: D
authors: Zhang
mesh_terms: D054058:Acute Coronary Syndrome / Q000150:complications / Q000188:drug therapy*; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069059:Atorvastatin / Q000008:administration & dosage / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000032:analysis; D002681:China; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy; D004359:Drug Therapy, Combination; D000069438:Ezetimibe / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000008:administration & dosage / Q000627:therapeutic use; D000068718:Rosuvastatin Calcium / Q000008:administration & dosage / Q000627:therapeutic use; D019821:Simvastatin / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein; D000069059:Atorvastatin; D019821:Simvastatin; D000069438:Ezetimibe; D017035:Pravastatin